Upgrade to SI Premium - Free Trial

Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following MDA conference 2026

March 9, 2026 3:22 PM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments